Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of April 2021, with a report date of April 16, 2021. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share acquisition transactions.
| Transaction Date | Instrument | Price per ADS | Total Volume (ADSs) | Exchange |
|---|---|---|---|---|
| April 15, 2021 | American Depositary Shares (ADSs) | $38.0538 | 4,507.409 (Aggregated) | New York Stock Exchange (XNYS) |
Transaction Breakdown by Individual:
- Mr. J. Ford (SVP & General Counsel): Acquired 152.309 ADSs.
- Mr. B. McNamara (CEO, GSK Consumer Healthcare): Acquired 2,101.593 ADSs.
- Ms. K. Terrell (Chief Digital & Technology Officer): Acquired 699.728 ADSs.
- Dr. H. Barron (Chief Scientific Officer and President, R&D): Acquired 1,553.779 ADSs.
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. The only reported activity is the acquisition of ADSs by four executives.
Guidance, Outlook, and Management Commentary
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The nature of all reported transactions was the "Acquisition of ADSs following the re-investment of dividends paid to shareholders on 8 April 2021."
Key Facts for Investor Verification
- Transaction Nature: All reported purchases were automatic dividend reinvestments, not discretionary open-market purchases.
- Market Price: The ADS price at the time of transaction was $38.0538.
- Executive Participation: Four senior executives participated in the dividend reinvestment plan on the same date.
- Financial Data: This filing does not contain quarterly or annual financial results; investors should refer to Form 20-F or earnings releases for financial performance data.